|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huang X, Yuan T, Liang M, Du M, Xia S,
Dittmar R, Wang D, See W, Costello BA, Quevedo F, et al: Exosomal
miR-1290 and miR-375 as prognostic markers in castration-resistant
prostate cancer. Eur Urol. 67:33–41. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jonas S and Izaurralde E: Towards a
molecular understanding of microRNA-mediated gene silencing. Nat
Rev Genet. 16:421–433. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lin S and Gregory RI: MicroRNA biogenesis
pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Romaine SP, Tomaszewski M, Condorelli G
and Samani NJ: MicroRNAs in cardiovascular disease: An introduction
for clinicians. Heart. 101:921–928. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cammaerts S, Strazisar M, De Rijk P and
Del Favero J: Genetic variants in microRNA genes: Impact on
microRNA expression, function, and disease. Front Genet. 6:1862015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu K, Huang J, Ni J, Song D, Ding M, Wang
J, Huang X and Li W: MALAT1 promotes osteosarcoma development by
regulation of HMGB1 via miR-142-3p and miR-129-5p. Cell Cycle.
16:578–587. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M,
et al: Human microRNA genes are frequently located at fragile sites
and genomic regions involved in cancers. Proc Natl Acad Sci USA.
101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Catto JW, Alcaraz A, Bjartell AS, De Vere
White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L,
Schlomm T, et al: MicroRNA in prostate, bladder, and kidney cancer:
A systematic review. Eur Urol. 59:671–681. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao G, Zhou X, Fang T, Hou Y and Hu Y:
Hyaluronic acid promotes the expression of progesterone receptor
membrane component 1 via epigenetic silencing of miR-139-5p in
human and rat granulosa cells. Biol Reprod. 91:1162014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Amemiya Y, Wallis CJ, Benatar T, Kobylecky
E, Sugar L, Sherman C, Nam R and Seth AK: Abstract A079:
MicroRNA-139 regulates prostate cancer aggressiveness by targeting
IGF1R. Cancer Res 78 (16 Supplement). A079. 2018.
|
|
14
|
Conley-LaComb MK, Semaan L, Singareddy R,
Li Y, Heath EI, Kim S, Cher ML and Chinni SR: Pharmacological
targeting of CXCL12/CXCR4 signaling in prostate cancer bone
metastasis. Mol Cancer. 15:682016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chansky K, Sculier JP, Crowley JJ, Giroux
D, Van Meerbeeck J and Goldstraw P; International Staging Committee
and Participating Institutions, : The International Association for
the Study of Lung Cancer Staging Project: Prognostic factors and
pathologic TNM stage in surgically managed non-small cell lung
cancer. J Thorac Oncol. 4:792–801. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Epstein JI, Zelefsky MJ, Sjoberg DD,
Nelson JB, Egevad L, Magi-Galluzzi C, Vickers AJ, Parwani AV,
Reuter VE, Fine SW, et al: A contemporary prostate cancer grading
system: A validated alternative to the Gleason score. Eur Urol.
69:428–435. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Higano C: Androgen deprivation therapy:
Monitoring and managing the complications. Hematol Oncol Clin North
Am. 20:909–923. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Agarwal V, Subtelny AO, Thiru P, Ulitsky I
and Bartel DP: Predicting microRNA targeting efficacy in
Drosophila. Genome Biol. 19:1522018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zuo Y, Li Y, Zhou Z, Ma M and Fu K: Long
non-coding RNA MALAT1 promotes proliferation and invasion via
targeting miR-129-5p in triple-negative breast cancer. Biomed
Pharmacother. 95:922–928. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang HD, Jiang LH, Sun DW, Li J and Tang
JH: MiR-139-5p: Promising biomarker for cancer. Tumour Biol.
36:1355–1365. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu S, Yi XM, Zhou WQ, Cheng W, Ge JP and
Zhang ZY: Downregulation of miR-129 in peripheral blood mononuclear
cells is a diagnostic and prognostic biomarker in prostate cancer.
Int J Clin Exp Pathol. 8:14335–14344. 2015.PubMed/NCBI
|
|
23
|
Pang C, Liu M, Fang W, Guo J, Zhang Z, Wu
P, Zhang Y and Wang J: MiR-139-5p is increased in the peripheral
blood of patients with prostate cancer. Cell Physiol Biochem.
39:1111–1117. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fizazi K, Scher HI, Molina A, Logothetis
CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F,
et al COU-AA-301 Investigators, : Abiraterone acetate for treatment
of metastatic castration-resistant prostate cancer: Final overall
survival analysis of the COU-AA-301 randomised, double-blind,
placebo-controlled phase 3 study. Lancet Oncol. 13:983–992. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mahammedi H, Planchat E, Pouget M, Durando
X, Curé H, Guy L, Van-Praagh I, Savareux L, Atger M, Bayet-Robert
M, et al: The new combination docetaxel, prednisone and curcumin in
patients with castration-resistant prostate cancer: A Pilot Phase
II Study. Oncology. 90:69–78. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wachter S, Gerstner N, Goldner G, Pötzi R,
Wambersie A and Pötter R: Rectal sequelae after conformal
radiotherapy of prostate cancer: Dose-volume histograms as
predictive factors. Radiother Oncol. 59:65–70. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dezhong L, Xiaoyi Z, Xianlian L, Hongyan
Z, Guohua Z, Bo S, Shenglei Z and Lian Z: miR-150 is a factor of
survival in prostate cancer patients. J BUON. 20:173–179.
2015.PubMed/NCBI
|
